Information  X 
Enter a valid email address

VASTox plc (SUMM)

  Print      Mail a friend

Monday 02 July, 2007

VASTox plc

Details of R&D Day - 24 July

VASTox plc
02 July 2007

                                   VASTox plc

                          ('VASTox' or 'the Company')

                VASTOX TO HOST R&D DAY ON 24 JULY 2007 IN LONDON

Oxford, UK, 2 July 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, is planning to hold an R&D day in London on 24 July 2007 for investors,
analysts and members of the press. The programme of presentations will cover
various aspects of VASTox's enhanced drug pipeline, its clinical programmes and
the potential of its zebrafish screening platform, following its recent
acquisitions of MNL Pharma, Daniolabs and Dextra Laboratories.

In addition, Professor Francesco Muntoni, Professor of Paediatric Neurology at
the Hammersmith Hospital, and Dr Paul Goldsmith, a consultant neurologist at
Addenbrookes Hospital, will provide clinical perspectives on the areas of
neuromuscular diseases and Parkinson's disease, respectively.

The event will be held at the offices of Huntsworth Health plc, 8th Floor, 26
Finsbury Square, London EC2A 1SF, beginning at 10.00hrs and followed by a buffet

For further information and to register interest in attending, please contact
Mark Swallow, Valerie Auffray or Janine Hagan at Citigate Dewe Rogerson on +44
(0)207 282 1068 or email

A preliminary programme is outlined below:

Dr Richard Storer,                        Overview of drug portfolio & twin technology platforms
Chief Scientific Officer, VASTox

Dr Paul Goldsmith                         Parkinson's Disease: Sialorrhoea and Seborrhoea. A
                                          clinicians perspective
Consultant Neurologist, Addenbrookes
Dr Nigel Blackburn                        The clinical development plan for the Parkinson's programmes
Director of Clinical Development, VASTox

Prof. Francesco Muntoni                   Neuromuscular diseases: a clinical focus
Paediatric Neurologist, Hammersmith
Hospital and Imperial College

Dr Jon Tinsley                            VASTox neuromuscular disease programmes: a focus on Duchenne
                                          muscular dustrophy
Director of Therapeutic Programmes,

Dr Richard Storer                         A Broad and diverse pipeline: VOX14400, Glaucoma and TB

Chief Scientific Officer, VASTox
Dr Alan Roach                             Zebrafish: the in vivo advantage

Director of Biology, VASTox
Prof Robert Nash                          Carbohydrates: an emerging technology for the development of
                                          new drugs
Director of Research, VASTox

                                    - ends -

For more information please contact:


Steven Lee, PhD, Chief Executive Officer                            Tel: +44 (0)1235 443951

Darren Millington, ACMA, Chief Financial Officer

Citigate Dewe Rogerson

Mark Swallow / David Dible / Valerie Auffray                        Tel: +44 (0)207 638 9571

Evolution Securities

Tim Worlledge / Bobbie Hilliam / Neil Elliot                        Tel: +44 (0)207 071 4300

About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX

Further information about the company is available at

This document contains 'forward-looking statements' within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as 'anticipates', 'intends', 'plans',
'seeks', 'believes', 'estimates', 'expects' and similar references to future
periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory

                      This information is provided by RNS
            The company news service from the London Stock Exchange